Incyte (INCY) Reports Q1 EPS of 12c, Updates FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Incyte (INCY) Reports Q1 EPS of 12c, Updates FY Guidance

Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs

May 9, 2016 7:00 AM EDT

$183 million of 2016 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 59 percent growth over the same period last year. Full year Jakafi net product revenue guidance increased from a range of $800-815 million to a range of $815-830 million. Recent agreements with Lilly and Novartis allow development of ruxolitinib for the treatment of graft versus host disease (GVHD); U.S. pivotal trial expected to begin in the second half of 2016. Expanded European organization via acquisition of ARIAD Pharmaceuticals European business Diversified and growing portfolio of cancer... More